Fragility fractures are a serious yet neglected complication of both Type 1 and Type 2 diabetes, the risk in people with diabetes extending across a patients’ lifespan.
This is a concern as, globally, the prevalence of diabetes in adults is expected to increase from almost 425 million today, to approximately 629 million by 2045.
At the same time, many clinicians who treat patients with diabetes are not aware of their patients’ heightened risk of disabling and potentially life-threatening fractures.
Given this scenario, the International Osteoporosis Foundation (IOF) Bone and Diabetes Working Group has published a new expert review that summarizes key research and provides a helpful guide for identification and management for patients at risk.
“The link between diabetes and skeletal health is complex and the optimal approach to the management of bone health in patients with diabetes is not yet definitive and may change over time as findings of new clinical studies become available,” says Serge Ferrari, chair of the IOF Committee of Scientific Advisors and of the IOF Bone and Diabetes Working Group.
“This new review will inform clinicians about the current state of knowledge, and, importantly, will facilitate the clinical assessment and management of fragility fracture risk in their patients according to current best practice,” he states.
The review outlines the clinical characteristics of bone fragility in adults with diabetes and highlights recent studies that have evaluated bone mineral density (BMD), bone microstructure and material properties, biochemical markers, and fracture prediction (FRAX).
It also looks at the impact of diabetes drugs on the bone, as well as the efficacy of osteoporosis treatments in these patients.